Seres Therapeutics
MCRB
About: Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
Employees: 103
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
783% more call options, than puts
Call options by funds: $2.23M | Put options by funds: $253K
24.4% more ownership
Funds ownership: 1.76% [Q1] → 26.17% (+24.4%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
31% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 13
41% less capital invested
Capital invested by funds: $43.1M [Q1] → $25.4M (-$17.7M) [Q2]
48% less funds holding
Funds holding: 63 [Q1] → 33 (-30) [Q2]
78% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 37
Financial journalist opinion
Based on 3 articles about MCRB published over the past 30 days
